GENFIT and Inventiva to join Euronext Paris CAC Mid 60 and SBF 120 indices

Biopharmaceutical companies GENFIT and Inventiva will be added to the CAC Mid 60 and SBF 120 indices on Euronext Paris following the annual index review. These changes are scheduled to take effect after the market closes on Friday, September 18, 2026, with the new composition becoming active on Monday, September 21, 2026.

GENFIT, which specializes in research and development for rare and life-threatening liver diseases, noted that the inclusion reflects growing investor confidence and increased market capitalization. The companies will replace Interparfums and Verallia in the SBF 120 and CAC Mid 60 indices. As a result of this promotion, both GENFIT and Inventiva will exit the CAC Small index.